Cargando…

Interactions between the ERK1/2 signaling pathway and PCAF play a key role in PE-induced cardiomyocyte hypertrophy

Cardiomyocyte hypertrophy is a compensatory phase of chronic heart failure that is induced by the activation of multiple signaling pathways. The extracellular signal-regulated protein kinase (ERK) signaling pathway is an important regulator of cardiomyocyte hypertrophy. In our previous study, it was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Qian, Wu, Shuqi, Peng, Chang, Peng, Bohui, Luo, Xiaomei, Huang, Lixin, Zhang, Huanting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281443/ https://www.ncbi.nlm.nih.gov/pubmed/34278478 http://dx.doi.org/10.3892/mmr.2021.12275

Ejemplares similares

JNK signaling-dependent regulation of histone acetylation are involved in anacardic acid alleviates cardiomyocyte hypertrophy induced by phenylephrine
por: Peng, Bohui, et al.
Publicado: (2021)

EGCG prevents pressure overload-induced myocardial remodeling by downregulating overexpression of HDAC5 in mice
por: Han, Xiao, et al.
Publicado: (2022)

Anacardic acid attenuates pressure‐overload cardiac hypertrophy through inhibiting histone acetylases
por: Li, Shuo, et al.
Publicado: (2019)

ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy
por: Gallo, Simona, et al.
Publicado: (2019)

PCAF interacts with XBP-1S and mediates XBP-1S-dependent transcription
por: Lew, Qiao Jing, et al.
Publicado: (2011)

Getting to the heart of the matter: CCN2 plays a role in cardiomyocyte hypertrophy
por: Leask, Andrew
Publicado: (2009)

Lactosylceramide promotes hypertrophy through ROS generation and activation of ERK1/2 in cardiomyocytes
por: Mishra, Sumita, et al.
Publicado: (2014)

Trans-cinnamaldehyde protects against phenylephrine-induced cardiomyocyte hypertrophy through the CaMKII/ERK pathway
por: Qian, Dongdong, et al.
Publicado: (2022)

PCAF Accelerates Vascular Senescence via the Hippo Signaling Pathway
por: Kong, Chaohua, et al.
Publicado: (2022)

Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice
por: Alharbi, Hajed O., et al.
Publicado: (2022)

The p53-HAT connection: PCAF rules?
por: Laptenko, Oleg, et al.
Publicado: (2012)

Discovery of a PCAF Bromodomain Chemical Probe
por: Moustakim, Moses, et al.
Publicado: (2016)

Posttranslational regulation of the GCN5 and PCAF acetyltransferases
por: Ononye, Onyekachi E., et al.
Publicado: (2022)

Coactivators p300 and PCAF physically and functionally interact with the foamy viral trans-activator
por: Bannert, Helmut, et al.
Publicado: (2004)

G9α‐dependent histone H3K9me3 hypomethylation promotes overexpression of cardiomyogenesis‐related genes in foetal mice
por: Peng, Bohui, et al.
Publicado: (2019)

SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle
por: Lu, Ya-Fei, et al.
Publicado: (2020)

Inhibiting O-GlcNAcylation impacts p38 and Erk1/2 signaling and perturbs cardiomyocyte hypertrophy
por: Papanicolaou, Kyriakos N., et al.
Publicado: (2023)

The transcriptional co-activator PCAF regulates cdk2 activity
por: Mateo, Francesca, et al.
Publicado: (2009)

Targeting the CaMKII/ERK Interaction in the Heart Prevents Cardiac Hypertrophy
por: Cipolletta, Ersilia, et al.
Publicado: (2015)

Pioglitazone Induces Cardiomyocyte Apoptosis and Inhibits Cardiomyocyte Hypertrophy Via VEGFR-2 Signaling Pathway
por: Zhong, Wenliang, et al.
Publicado: (2018)

Complementary Roles of GCN5 and PCAF in Foxp3+ T-Regulatory Cells
por: Liu, Yujie, et al.
Publicado: (2019)

PCAF fine‐tunes hepatic metabolic syndrome, inflammatory disease, and cancer
por: Wang, Tongxin, et al.
Publicado: (2018)

Acetyltransferases GCN5 and PCAF Are Required for B Lymphocyte Maturation in Mice
por: Oksenych, Valentyn, et al.
Publicado: (2021)

The role of angiopoietin-like protein 4 in phenylephrine-induced cardiomyocyte hypertrophy
por: Sun, Yu, et al.
Publicado: (2019)

Salidroside Ameliorates Cardiomyocyte Hypertrophy by Upregulating Peroxisome Proliferator-Activated Receptor-α
por: Gao, Hui, et al.
Publicado: (2022)

HMGB1 enhances mechanical stress-induced cardiomyocyte hypertrophy in vitro via the RAGE/ERK1/2 signaling pathway
por: Zhang, Lei, et al.
Publicado: (2019)

Role of Histone Demethylases in Cardiomyocytes Induced to Hypertrophy
por: Rosales, Wendy, et al.
Publicado: (2016)

Lycopene Inhibits Urotensin-II-Induced Cardiomyocyte Hypertrophy in Neonatal Rat Cardiomyocytes
por: Chao, Hung-Hsing, et al.
Publicado: (2014)

Effect of ligustilide on Ang II-induced hypertrophy in cardiomyocytes and the potential mechanisms
por: LU, QUN, et al.
Publicado: (2014)

Inhibition of Receptor Interacting Protein Kinases Attenuates Cardiomyocyte Hypertrophy Induced by Palmitic Acid
por: Zhao, Mingyue, et al.
Publicado: (2016)

GCN5 inhibits XBP-1S-mediated transcription by antagonizing PCAF action
por: Lew, Qiao Jing, et al.
Publicado: (2014)

The epigenetic factor PCAF regulates vascular inflammation and is essential for intimal hyperplasia development
por: de Jong, Rob C. M., et al.
Publicado: (2017)

Influenza A virus nucleoprotein is acetylated by histone acetyltransferases PCAF and GCN5
por: Hatakeyama, Dai, et al.
Publicado: (2018)

Opposite effects of GCN5 and PCAF knockdowns on the alternative mechanism of telomere maintenance
por: Jeitany, Maya, et al.
Publicado: (2017)

PE-induced apoptosis in SMMC-7721 cells: Involvement of Erk and Stat signalling pathways
por: XUE, LI, et al.
Publicado: (2014)

Profilin modulates sarcomeric organization and mediates cardiomyocyte hypertrophy
por: Kooij, Viola, et al.
Publicado: (2016)

miR-218 Involvement in Cardiomyocyte Hypertrophy Is Likely through Targeting REST
por: Liu, Jing-Jing, et al.
Publicado: (2016)

The cardiac translational landscape reveals that micropeptides are new players involved in cardiomyocyte hypertrophy
por: Yan, Youchen, et al.
Publicado: (2021)

ERK plays the baddie (again)
por: Dent, Paul
Publicado: (2013)

Pulmonary valve papillary fibroelastoma: to PE or not to PE
por: Kirk, Frazer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ukel4jks6p3barf8l30anh5ob4